Combined α-programmed death-1 monoclonal antibody blockade and fractionated radiation therapy reduces tumor growth in mouse EL4 lymphoma.
Xiuyun Lin,Tao Zeng,Jiani Xiong,Qiong Zhang,Pan Jiang,Xiufeng Li,Shuchun Lin,Qianqian Xu,Huanjiao Weng,Haichun Lai,Huichun Gong,Jinxiang Lin,Niangmei Cheng,Xinling Tian,Yunlu Xu,Shubin Fang,Rong Jin,Zhiwei Chen,Jianbo Yang,Luke Morton,Bevan Yueh,Jizhen Lin
DOI: https://doi.org/10.1080/15384047.2018.1550569
2019-01-01
Cancer Biology & Therapy
Abstract:The programmed death (PD) pathway is frequently present in the tumor microenvironment (TME) and suppresses tumor immunity by inhibiting the activity of tumor-infiltrating lymphocytes (TILs), particularly, CD8(+) lymphocytes. PD immunotherapy involves stimulation of the immune response in the region surrounding the tumor but is insufficient to prevent tumor progression. Therefore, in this study, we examined the effects of combined PD immunotherapy with fractionated radiotherapy (RT) on antitumor immunity and tumor growth in lymphoma. The immune cell profiles of the TME, blood, and secondary lymphoid organs were determined 7 days after treatment. Four combination therapies were compared. The synergistic effects of alpha PD-1 mAb and fractionated RT on increased CD8(+) lymphocytes in the TME, blood, and secondary lymphoid organs led to substantial tumor regression in mouse EL4 lymphoma, both locally and systemically. Fractionated RT for 4 days followed by alpha PD-1 mAb therapy was significantly superior to other schemes in terms of overall survival rates and curative rates in xenograft model mice. Our data indicated that substantial immune responses occurred following combination therapy with fractionated RT and alpha PD-1 mAb immunotherapy. Our findings provide important insights into the use of RT plus alpha PD-1 mAb as an efficacious combinatorial therapy.